The incidence of BM has been reported to be higher (46%) in patients with advanced TNBC than in HR-positive and HER2-positive subtypes of BC [30], but the risk in patients with the HR-negative/HER2-positive subtype is as high as in patients with the TNBC subtype [31,32,33]. Here, ERBB2 is linked to breast cancer.